← Back to Screener
NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)
Price$0.72
Favorite Metrics
Price vs S&P 500 (26W)-48.69%
Price vs S&P 500 (4W)-12.32%
Market Capitalization$25.10M
All Metrics
Book Value / Share (Quarterly)$0.11
P/TBV (Annual)1.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.44
Price vs S&P 500 (YTD)-11.60%
EPS (TTM)$-0.62
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-0.62
EPS (Annual)$-0.44
ROI (Annual)-395.74%
Cash / Share (Quarterly)$0.15
ROA (Last FY)-222.93%
EBITD / Share (TTM)$-0.62
ROE (5Y Avg)-244.31%
Cash Flow / Share (Annual)$-0.44
P/B Ratio9.72x
P/B Ratio (Quarterly)10.74x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-326.21x
ROA (TTM)-841.92%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)2.21x
Quick Ratio (Quarterly)2.17x
3-Month Avg Trading Volume0.22M
52-Week Price Return-31.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.12
52-Week High$2.60
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)-4.36%
26-Week Price Return-41.80%
Quick Ratio (Annual)2.17x
13-Week Price Return-28.36%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.21x
Enterprise Value$21.72
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.15
3-Month Return Std Dev68.83%
Net Income / Employee (TTM)$-1
ROE (Last FY)-395.74%
Net Interest Coverage (Annual)-276.79x
EPS Basic Excl Extra (Annual)$-0.44
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.62
ROI (TTM)-395.28%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.48
Price vs S&P 500 (52W)-65.90%
Year-to-Date Return-7.67%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-219.60%
Month-to-Date Return-5.96%
EBITD / Share (Annual)$-0.43
LT Debt / Equity (Annual)2.62x
ROI (5Y Avg)-242.73%
EPS Basic Excl Extra (TTM)$-0.62
P/B Ratio (Annual)10.71x
Book Value / Share (Annual)$0.11
Price vs S&P 500 (13W)-30.74%
Beta1.50x
Revenue / Share (TTM)$0.00
ROE (TTM)-395.28%
52-Week Low$0.63
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.11
4.10
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NRSNNeuroSense Therapeutics Ltd. Ordinary Shares | — | — | — | — | $0.72 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $899.91 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $224.87 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $205.74 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $112.62 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $196.15 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $148.70 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $38.87 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $94.12 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.37 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $58.80 |
About
NeuroSense Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases including ALS, Alzheimer's disease, and Parkinson's disease. Its lead candidate, PrimeC, is a novel extended-release oral formulation combining two FDA-approved generic drugs—ciprofloxacin and celecoxib—in a proprietary fixed-dose combination designed to treat these conditions.